Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence

Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence

Abstract de Boer and colleagues present a cost-effectiveness analysis based in the Netherlands of two vaccines available for the prevention of herpes zoster. Zostavax® was the first vaccine available for the prevention of herpes zoster in older adults. A live-attenuated vaccine, Zostavax is not free...

Full description

Bibliographic Details
Main Authors: Chester B. Good, Natasha Parekh, Inmaculada Hernandez
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Medicine
Subjects:
Vaccine
Immunization
Herpes zoster
Cost-effectiveness
Decision-making
Online Access:http://link.springer.com/article/10.1186/s12916-018-1231-3

Internet

http://link.springer.com/article/10.1186/s12916-018-1231-3

Similar Items